Background: Minocycline, a derivative of tetracycline, has anti- () properties and can be used to treat infection. However, only a few randomized controlled trials (RCTs) have investigated the efficacy of minocycline-containing quadruple therapy (MCQT) in treating infection. This study aimed to determine the efficacy and safety of MCQT and investigate the factors influencing both aspects.
Methods: This was a retrospective cohort study. Patients diagnosed with infection between January 1, 2022, and July 31, 2023 at. The primary outcome was the eradication rate of , and the secondary outcome was the number and type of adverse events.
Results: A total of 828 patients were included in this study. The overall eradication rate among the included patients at 95% confidence interval (CI) (Range 0.864 to 0.907) was 88.53%. The eradication rate for patients who received MCQT regimen as the primary therapy was 92.28% (95% CI: 0.901-0.945), significantly higher than that of patients who received MCQT as rescue therapy (80.81%; 95% CI: 0.761-0.855, 0.003). Adverse events, including dizziness, abdominal distension, diarrhea, nausea, abdominal discomfort, constipation, headache, rash, sleep disorder, palpitation, backache, and anorexia, occurred in 185 (22.34%) patients, with dizziness being the most common (75/828, 9.06%). Compliance with MCQT therapy was an independent factor influencing eradication in patients receiving MCQT as a primary therapy. Compliance and presence or absence of infection symptoms at the time of screening were independent factors influencing eradication in patients receiving MCQT as rescue therapy. Factors that influenced the occurrence of adverse events included reasons for infection screening, residence, treatment compliance, and the use of acid-suppressant regimens.
Conclusion: MCQT regimens were effective in infection eradication, and the treatment resulted only in fewer adverse events when used as primary or rescue therapies for infection treatment. Future prospective studies with larger sample sizes and more comprehensive data are needed to validate our findings.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11198024 | PMC |
| http://dx.doi.org/10.2147/IDR.S457618 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Aerosolized plus intravenous polymyxin B in comparison to intravenous polymyxin B alone for the management of HAP caused by carbapenem-resistant gram-negative bacteria: a prospective multicenter cohort study.
Int J Antimicrob Agents
December 2024
Department of Critical Care Medicine, the Second Affiliated Hospital of Xi'an Jiaotong University, China. Electronic address:
Objectives: This study aimed to evaluate the clinical effectiveness of combined aerosolized (AER) and intravenous (IV) polymyxin B in managing patients with hospital-acquired pneumonia (HAP) caused by carbapenem-resistant gram-negative organism (CRO) .
Methods: This multicenter prospective cohort study was conducted across six intensive care units in municipal and above-municipal hospitals in Shaanxi, China, from January 1, 2021 to December 31, 2022. Patients with CRO pneumonia were categorized into the intravenous group (IV polymyxin B alone) and the combination group (AER plus IV polymyxin B).
Ten-day vonoprazan-amoxicillin dual therapy versus 14-day esomeprazole-amoxicillin dual therapy for first-line eradication: a prospective multicenter randomized controlled trial.
Therap Adv Gastroenterol
December 2024
Department of Gastroenterology, Affiliated Hospital of Yangzhou University, Yangzhou University, No.368, Hanjiang Middle Road, Hanjiang District, Yangzhou, Jiangsu, China.
Background: The efficacy of the 14-day esomeprazole-amoxicillin (EA) dual therapy in eradicating () has been widely discussed previously. Vonoprazan, a novel potassium-competitive acid blocker, presents rapid, potent, and long-lasting acid inhibitory effects compared to esomeprazole. However, there is currently a scarcity of direct comparisons between the 10-day vonoprazan-amoxicillin (VA) and the 14-day EA dual therapy for eradication.
View Article and Find Full Text PDFAscorbate-loaded MgFe layered double hydroxide for osteomyelitis treatment.
J Control Release
December 2024
Department of Traumatology and Orthopaedic Surgery, Huizhou Central People's Hospital, Huizhou 516001, China; Hui Zhou-Hong Kong Bone Health Joint Research Center, Institute of Orthopaedics, Huizhou Central People's Hospital, Huizhou 516001, China. Electronic address:
Article Synopsis
- Bacterial infections pose major challenges in orthopedic treatments, as traditional antibiotics can damage cells and lead to resistance.
- A new nanoenzyme-mimicking drug, AA@LDH, has been developed that combines magnesium iron layered double hydroxide with ascorbic acid, effectively generating reactive oxygen species to kill bacteria like S. aureus and E. coli.
- This system not only significantly reduces bacterial presence but also promotes bone healing by enhancing cell function and supporting tissue regeneration, representing a promising advancement in medical treatments.
Application of 3D-printed porous prosthesis for the reconstruction of infectious bone defect with concomitant severe soft tissue lesion: a case series of 13 cases.
BMC Musculoskelet Disord
December 2024
Department of Orthopedics, Peking University Third Hospital, No.49, North Garden Rd, HaiDian District, Beijing, 100191, China.
Background: Treating infectious bone defects combined with large soft-tissue lesions poses significant clinical challenges. Herein, we introduced a modified two-stage treatment approach involving the implantation of 3D-printed prostheses and flap repair to treat large segmental infectious tibial bone defects.
Method: We conducted a retrospective study of 13 patients treated at our center between April 2018 and March 2022 for tibial infections owing to posttraumatic infection and chronic osteomyelitis combined with soft tissue defects.
Time trends in malaria incidence from 1992 to 2021 in high-risk regions: an age‑period‑cohort analysis based on the Global Burden of Disease study 2021.
Int J Infect Dis
December 2024
Department of Epidemiology & Health Statistics, School of Public Health, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China; Jiangxi Provincial Key Laboratory of Disease Prevention and Public Health, Nanchang University, Nanchang, China. Electronic address:
Objectives: Malaria, caused by plasmodium parasites, remains one of the world's most significant infectious diseases due to its high incidence and mortality. This study aims to analyze malaria incidence globally, identify high-risk regions, and examine long-term trends in incidence to provide important evidence for malaria eradication.
Methods: We used data from the Global Burden of Disease Study (GBD) 2021, applying the age-period-cohort model to estimate the effects of age, period and cohort on malaria incidence from 1992 to 2021.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!